A Study of Efficacy and Safety of AND017 in Patients with Myelodysplastic Syndrome
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, randomized, open-lable, dose ranging study to evaluate the efficacy and safety of AND017 for the treatment of anemia due to lower risk Myelodysplastic syndromes (MDS) in patients subjects who are Red blood cell (RBC) non-transfusion dependent (NTD) and low transfusion burden (LTB).